Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of niraparib versus physician's choice chemotherapy in germline BRCA-mutated HER2-negative advanced breast cancer
NL-OMON45039Phase 3Active, not recruiting
- Sponsor
- TESARO, Inc.
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of niraparib in breast cancer (2 arms), sponsored by TESARO, Inc. Primary endpoint: Progression-free survival. Started Sep 2014; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45039.